Lennmyr E, et al. - Researchers examined 933 patients (median age 53 years) who received the diagnosis of acute lymphoblastic leukemia (ALL) between 1997 and 2015 to assess features, treatment and long-term outcome in these subjects. They used data from the population-based Swedish ALL registry. Findings revealed an improvement in 5-year overall survival (OS) between 1997-2006 and 2007-2015. In patients who survived five years from diagnosis, the reported standardized mortality ratio was 5.7. Impaired prognosis was not linked with Philadelphia (Ph)-positive disease; Ph-positive disease was related to a lower risk of mortality in 2007-2015. In adult ALL, improved OS was reported in a population-based cohort, particularly for Ph-positive disease. A poor outcome was evident in middle-aged men with Ph-negative B-ALL. There is still a need for cure without late toxicity or relapse.